On May 24, analysts at Stifel reaffirmed their Buy rating and price target of $48 for Bicara Therapeutics Inc. (NASDAQ:BCAX).

and on Friday a three-person arbitration panel ruled Stifel Nicolaus & Co. Inc. pay $7 million in legal costs of advisors who left the firm in 2023 and then were sued by the firm. It’s the ...

The St. Louis-based financial services giant has inked what officials called an "unprecedented" extension of its sponsorship ...

The competing legal strategies appear contrary to Stifel’s public statements about defending its structured notes’ tactics.

Citing what they call the S&P 500 price-to-earnings mania, Stifel is once again recommending that what it calls “defensive ...

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced management will participate in the ...

Stifel Nicolaus lowered their target price on shares ... company’s stock valued at $41,000 after purchasing an additional 1,225 shares during the last quarter. KBC Group NV increased its ...

In addition to Stifel Nicolaus, Intel also received a Hold from Bank of America Securities’s Vivek Arya in a report issued today. However, on the same day, Rosenblatt Securities maintained a ...

Stifel Nicolaus analyst J. Parker Lane maintained a Buy rating on Guidewire (GWRE – Research Report) today and set a price target of $230.00. See what stocks are receiving Strong Buy ratings ...

Stifel Nicolaus analyst Simon Yarmak maintained a Buy rating on Pebblebrook Hotel (PEB – Research Report) today and set a price target of $16.50. The company’s shares closed yesterday at $11.75.